Hepatic Encephalopathy Market Analysis By Drug Class (Antibiotics, Laxatives, L-ornithine, L-aspartate, Others), By Route of Administration (Oral, Intravenous, Rectal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Forecast

  • 24/03/2023
  • 256
  • Healthcare & Life Sciences
Market Overview:
The global hepatic encephalopathy market size was valued at USD 400 million in 2021 and is projected to reach around USD 600 million in 2030 exhibiting a CAGR of 5.5% in the forecasted period. The key factors disturbing the industrial growth include the escalating incidence of neurological diseases globally, growing unmet treatment needs and augmented demand for better and effective treatments are factors expected to driving market growth. Also, growing prevalence of chronic liver diseases can be one of the aspects contributing to the global hepatic encephalopathy treatment market growth over to forecast period. However, shortage of competent medical personnel, beside an unfavourable reimbursement environment in emerging and underdeveloped nations, will establish a significant obstacle to revenue growth of the market.
As decompensated cirrhosis is now acknowledged as a systemic illness with multi-organ dysfunction linked with underactive inflammation, a diversity of mechanistic methods to avoid disease development in decompensated cirrhosis patients have been examined. For example, in September 2020, Copenhagen University Hospital, Hvidovre informed that clinical studies for, Statins for the Prevention of Liver Cirrhosis Disease Progression and Hospitalization (STATLiver) is in Phase 4 and the study is projected to be finished by December 2028. The success of this education can greatly impact the global market revenue.
An upsurge in the rate of strategic partnership among market players is major opportunity for the market to grow considerably. Another indirect flexible that will produce attractive market development potential is surge in the filing of Abbreviated New Drug Application (ANDA). Moreover, increasing number of clinical studies and fast discovery of new medicines are boosting market participants to work different methods to enhance their market position and range their product line. These aspects are expected to contribute to revenue growth of the hepatic encephalopathy market during the forecasted period.

The covid-19 outbreak is anticipated to have a long-term impact on the growth of hepatic encephalopathy as people suffering from cirrhosis disease need extreme preventive care which was affected by the due spread of coronavirus. It affected the process established to offer good care to the patients.

Drug Class Insights
Global hepatic encephalopathy market is segmented into antibiotics, laxatives, L-ornithine, L-aspartate, and others. The market was dominated by the segment of antibiotics. The antibiotics segment accounted for the largest market share in 2021. The segment growth can be accredited to its capability to decrease ammonia manufacturing in the intestine by generating a hostile for the bad microbes in the intestine.

Region Insights
North America is projected to account for maximum revenue share during the forecast period. The region's early acceptance of breakthrough technologies, growing prevalence of liver illnesses, and escalating research and development capability all contribute to the increasing market share of the region. As per the National Center for Biotechnology Information (NCBI), in September 2020, nearly 7-11 million cases of hepatic encephalopathy were diagnosed in the U.S., with about 150,000 people newly diagnosed every year. About 20% of recently detected patients have liver cirrhosis, and almost 60% have chronic hepatitis C, each alone or in conjunction with alcohol-related liver illness. Moreover, marks of hepatic encephalopathy are available in about 70% of individuals with liver cirrhosis.
The increase in healthcare expenditure and expansion in healthcare infrastructure, together with the favourable regulatory status, have aided the regional market. Moreover, growth in community awareness of liver illness and liver cancer has raised regional income even more. Furthermore, the existence of important market players gives a benefit to the region to allow the novel treatment substitutes. These factors are expected to drive revenue growth of the region during the forecast period.
Asia Pacific is anticipated to grow with the greatest CAGR over the forecasted period. This is owing to augmented healthcare infrastructure construction prices, upsurge in neurological illnesses, and increase in research and development efforts for the detection and treatment of liver diseases.
Additionally, alcohol consumption is highest in the Asia Pacific region, among more urbanized countries and territories. This leads to a high number of patients living with liver diseases, rushing the demand for appropriate treatment. All these factors are anticipated to support revenue growth of the region during the forecasted period.

Key Companies Insights
The market for hepatic encephalopathy is moderately competitive. With the rising applications of hepatic encephalopathy, new players are considering to enter the market. The companies are also involved in events like acquisitions, joint ventures, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the hepatic encephalopathy market, ultimately boosting the market growth.

Some of the key companies working in the global hepatic encephalopathy market include:
• Mallinckrodt Pharmaceuticals
• Lupin
• Salix Pharmaceuticals
• Umecrine Cognition AB
• Norgine B.V.
• Ferring B.V.
• Pfizer Inc.
• Bausch Health Companies, Inc.
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc.
• Merck & Co., Inc.,
• Johnson & Johnson Services, Inc.
• Hikma Pharmaceuticals PLC
• ASKA Pharmaceutical Co., Ltd.
• Amgen Inc.
• AbbVie Inc.
• Other players

Some of the Recent Developments:
• In April 2020, Umecrine Cognition AB issued exceptional findings for a phase IIa clinical study of the therapeutic candidate golexanolone on patients at risk of emerging hepatic encephalopathy
• In March 2020, Zydus Cadila received support for new drug application for Saroglitazar to treat a precise liver disease by the Medication Controller General of India (DCGI. The official medicine is the first in the world to treat Non-Cirrhotic Non-Alcoholic Steato-Hepatitis (NASH), a degenerative liver disorder.
• In March 2020, Bausch Health Companies Inc. broadcasted topline results from a Phase 2 study evaluating an investigational soluble solid dispersion (SSD) formulation of immediate release (IR) rifaximin in combination therapy.
• In March 2019, Bausch Health Companies Inc. stated that it has confirmed the acquisition of certain assets from Synergy Pharmaceuticals Inc. The transaction was worth USD 195 million. Bausch Health Companies Inc. made the deal to expand its gastrointestinal portfolio.

By Drug Class
• Antibiotics
• Laxatives
• L-ornithine
• L-aspartate
• Others

By Route of Administration
• Oral
• Intravenous
• Rectal

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
• Latin America
o Brazil
o Argentina
o Colombia
o South Africa
o Saudi Arabia
o Egypt

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process

We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).


The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.

Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.


Select a license type that suits your business needs

Single User Access

US $4250

Only Four Thousand Two Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $5250

Only Five Thousand Two Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $6250

Only Six Thousand Two Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI